William Snider, a director at Harvard Bioscience, reported purchases of 21,000 common shares. The shares were acquired at weighted average prices of USD 4.99 and USD 4.85. Following the reported transactions, Snider beneficially owned 32,000 common shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harvard Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-001689), on March 18, 2026, and is solely responsible for the information contained therein.
Comments